VKTX shares jump after early obesity-injection data optimism
Viking Therapeutics said early data for VK2735 (obesity injection) suggested most patients kept most weight off with every-other-week dosing or monthly dosing; Oppenheimer raised its target amid optimistic Wall Street commentary.
Shares of Viking Therapeutics (VKTX) climbed on Tuesday after early data showed its experimental obesity injection, VK2735, kept most patients’ weight off when they took it every other week or once a month, prompting optimistic Wall Street commentary and a price target upgrade. The San Diego company i…